Thursday, 28 October 2021


Agios, Celgene terminate partnership for developing cancer treatment

06 September 2018 | News

Celgene will be eligible to receive low single-digit royalties on global net sales and both companies will split certain global development costs until year-end.

Image Courtesy- sourceable.net

Image Courtesy- sourceable.net

 Singapore - Agios Pharmaceuticals and Celgene have mutually agreed to terminate their collaboration and license agreement inked on April 27, 2015, to develop and commercialize products containing pan-IDH inhibitor AG-881.

Global rights will revert back to Agios. Celgene will be eligible to receive low single-digit royalties on global net sales and both companies will split certain global development costs until year-end.

For a specific time period (undisclosed), Celgene and its affiliates will be prohibited from developing, manufacturing or commercializing any product containing isocitrate dehydrogenase 1 (IDH1) at specific levels of binding for any indication. Agios will be prohibited from developing, manufacturing or commercializing AG-881 in blood cancers.

The termination comes three months after Agios presented its first data from an ongoing Phase I study (NCT02481154) assessing AG-881 as a single agent in advanced glioma and other solid tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account